FNC
GNCA

First National Corp’s Genocea Biosciences, Inc. GNCA Stock Holding History

First National Corp’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-56
Closed – – 480
2019
Q1 		$0 Buy
+56
New +$277 ﹤0.01% 523

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

First National Corp's GNCA Position: Q2 2019 in Review

First National Corp sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2019, closing a stake of 56 shares.

First National Corp first reported a position in GNCA in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 45 funds tracked by Wall St. Rank hold GNCA as of Q2 2019.

  • First National Corp reported no remaining Genocea Biosciences, Inc. position as of Q2 2019 after selling out during the quarter.
  • First National Corp sold 56 Genocea Biosciences, Inc. shares in Q2 2019.
  • First National Corp first reported a position in Genocea Biosciences, Inc. in Q1 2019 and held it in 1 quarter.
  • First National Corp's Genocea Biosciences, Inc. position peaked at $0 in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2019.

Based on First National Corp's 13F filing for Q2 2019, filed 30 Jul 2019.